Increased basal levels of ROS in EGFR-driven GBM with EGFRvIII expression [29] and EGFR amplification [30] suggest a potential relationship between EGFR alterations and basal GSH antioxidant capacity in GBM. The gene discussed is EGFR; the disease is glioblastoma.